NASDAQ · Biotechnology

ALLO (ALLO) Stock

$1.95 +2.63% NASDAQ: ALLO Healthcare

Valuation

MetricValue
Price$1.95
Market Cap$673.05M
P/E Ratio-2.17
P/B Ratio1.57
P/S Ratio0.00
EPS (TTM)$-0.87
52-Week High$4.46
52-Week Low$0.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-65.19%
ROA-45.91%
ROCE-70.65%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.29
Current Ratio7.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$114.0M$0$0$0$0
Operating Profit$-180.0M$-336.0M$-328.0M$-273.0M$-207.0M
Net Profit$-182.0M$-340.0M$-327.0M$-258.0M$-191.0M
EPS$-1.34$-2.38$-2.09$-1.32$-0.87
Op Margin-157.9%-215087.2%-344986.3%-1241813.6%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$822.0M$643.0M$549.0M$416.0M
Total Liabilities$126.0M$155.0M$131.0M$127.0M$123.0M
Cash$173.0M$62.0M$83.0M$75.0M$52.0M
Borrowings$73.0M$101.0M$95.0M$91.0M$75.0M

Latest News

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors GlobeNewswire · Jul 15, 2026 Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial Exec Edge · Jun 30, 2026 Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions Simply Wall St. · Jun 28, 2026 How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease Insider Monkey · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-185.0M$-221.0M$-238.0M$-200.0M$-149.0M
Investing Cash Flow$142.0M$101.0M$162.0M$75.0M$95.0M
Financing Cash Flow$0$0$5.0M$2.0M$7.0M
Net Cash Flow$-9.0M$-111.0M$21.0M$-8.0M$-24.0M
Free Cash Flow$-206.0M$-226.0M$-239.0M$-201.0M$-150.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-23.51%
Quick Ratio9.65
Interest Coverage-207.00
Return 1Y9.64%
Return 3Y-63.16%
Return 5Y-91.72%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHV $6.66 +2.94% -4.63 $683.71M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
EDIT $2.62 -2.24% -1.39 $256.50M 0.00%

About ALLO

ALLO is led by CEO David D. Chang, publicly traded since 2018.

ALLO stock trades at $1.95 with a market capitalization of $673.05M. The stock is valued at a price-to-earnings (P/E) ratio of -2.17, price-to-book of 1.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.98 and $4.46, and currently trades 56.3% below its 52-week high.

On profitability, ALLO generates a return on equity (ROE) of -65.19%, return on capital employed of -70.65%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides